Amy Parison
Known title: SVP, Chief Financial OfficerCIK: 0002063082
Associated companies
Transaction History
| EDIT | ▼ Sell | Open Market | 453 | $1K | 9/3/2026 | View on chart |
| EDIT | ▼ Sell | Open Market | 678 | $2K | 8/3/2026 | View on chart |
| EDIT | ▼ Sell | Open Market | 464 | $1K | 6/3/2026 | View on chart |
| EDIT | ▼ Sell | Open Market | 474 | $957 | 3/3/2026 | View on chart |
| EDIT | ▼ Sell | Open Market | 461 | $993 | 12/3/2025 | View on chart |
| EDIT | ▼ Sell | Open Market | 458 | $1K | 9/3/2025 | View on chart |
| EDIT | ▼ Sell | Open Market | 679 | $2K | 8/7/2025 | View on chart |
| EDIT | ▼ Sell | Open Market | 446 | $769 | 6/3/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Editas Medicine upgraded to Buy with $5 price target
Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, citing a planned BLA filing in 2027 and progress with PM647. This move came as gene-editing stocks faced broader pressure from recent AI-related news. The upgrade aligns with the current average analyst target of $5.90, providing a positive fundamental signal for the stock.
Editas Medicine upgraded to Buy with $5 price target. Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, citing a planned BLA filing in 2027 and progress with PM647. This move came as gene-editing stocks faced broader pressure from recent AI-related news. The upgrade aligns with the current average analyst target of $5.90, providing a positive fundamental signal for the stock.